Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase - Quiz - MDSpire

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase

  • By

  • Alexa B. Kimball

  • Konrad T. Sawicki

  • Lindsay Ackerman

  • Hermenio Lima

  • Evangelos J. Giamarellos-Bourboulis

  • Tianyu Zhan

  • Leonidas Drogaris

  • Yihua Gu

  • Christine M. Lee

  • Mona Akbari

  • David A. Williams

  • Falk G. Bechara

  • May 1, 2026

  • 0 min

Share

Original Source(s)

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase

  • by Alexa B. Kimball, Konrad T. Sawicki, Lindsay Ackerman, Hermenio Lima, Evangelos J. Giamarellos-Bourboulis, Tianyu Zhan, Leonidas Drogaris, Yihua Gu, Christine M. Lee, Mona Akbari, David A. Williams, Falk G. Bechara

  • May 1, 2026

Related Content

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

Psychiatric and Psychological Care Utilization Among Patients with Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis: Insights from a Propensity-Matched Real-World Cohort Analysis

Exploring the Role of the TL1A-DR3 Pathway in Hidradenitis Suppurativa